The TOR pathway: a target for cancer therapy

Nat Rev Cancer. 2004 May;4(5):335-48. doi: 10.1038/nrc1362.

Authors

Mary-Ann Bjornsti¹, Peter J Houghton

Affiliation

¹ Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

PMID: 15122205
DOI: 10.1038/nrc1362

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Antibiotics, Antineoplastic / pharmacology
Cell Transformation, Neoplastic* / drug effects
Humans
Phosphatidylinositol 3-Kinases / physiology
Protein Kinases / physiology*
Protein Serine-Threonine Kinases / physiology
Signal Transduction / physiology*
Sirolimus / pharmacology
TOR Serine-Threonine Kinases
Tacrolimus Binding Proteins / physiology*

Substances

Antibiotics, Antineoplastic
Protein Kinases
MTOR protein, human
Protein Serine-Threonine Kinases
TOR Serine-Threonine Kinases
Tacrolimus Binding Proteins
Sirolimus